# BPC-157 Dosage in the Research Literature > BPC-157 dosage in published preclinical studies: 10 μg/kg most common in rodent models, route comparisons, half-life data, and oral vs injectable bioavailability — cited throughout. ## Research Doses: What Studies Have Used BPC-157 dosage in the published literature is almost entirely preclinical. The most common dose across the rodent literature is 10 μg/kg per day via intraperitoneal injection — the dose appearing in the Sikiric group's tendon, ligament, muscle, GI, spinal cord, cardiac, and hepatic studies [4][5][6][7][9][10][11]. A key observation from multiple dose-comparison studies is equi-potency across a 1,000-fold range: 10 ng/kg produces similar outcomes to 10 μg/kg in several models, including ligament healing and wound closure [4][12]. This equi-potency is unusual and noted in the literature as a characteristic of BPC-157's dose-response profile — it is not a dose-dependent linear relationship. The human pilot studies have used substantially different dose forms: 10 mg intravesicular (interstitial cystitis, 2024) [20] and 10-20 mg intravenous (safety pilot, 2025). No extrapolation between rodent μg/kg doses and human mg doses has been validated. BPC-157 is not FDA-approved for any human indication. This section describes what research protocols have used — not what is appropriate for human administration. ## BPC-157 Half-Life and Pharmacokinetics A 2022 pharmacokinetic study in rats and beagle dogs published in Frontiers in Pharmacology provided the most systematic PK characterization of BPC-157 to date [19]. Key findings: **Elimination half-life:** 15.2 minutes in rats (IV); 5.27 minutes in beagle dogs (IV). Half-life is substantially shorter in dogs than rats — species difference likely reflects differential hepatic metabolism. **Intramuscular bioavailability:** 14-19% in rats; 45-51% in beagle dogs. The large species gap in IM bioavailability underscores why PK extrapolation across species — and especially to humans — is not yet validated. **Clearance:** BPC-157 is metabolized in the liver and cleared renally. Linear pharmacokinetics were observed across all tested doses (20, 100, 500 μg/kg IM). **Plasma levels:** In the two-person human IV safety pilot, plasma levels returned to baseline within 24 hours, consistent with the animal data showing rapid clearance. The short plasma half-life (minutes) is notable given that the tissue-repair effects observed in rodent studies persist over days to weeks. ## Oral vs Injectable Administration in Research Studies BPC-157's gastric-protein origin confers unusual oral stability for a peptide. Research studies have confirmed activity via multiple non-parenteral routes: **Oral gavage.** The colocutaneous fistula study by Klicek et al. (2008) used both intraperitoneal and peroral (drinking water) administration at 10 μg/kg and 10 ng/kg, with similar outcomes across both routes [11]. The wound-healing review by Seiwerth et al. (2021) confirmed equi-potent oral effects across wound types [12]. **Drinking water (continuous oral).** Several Sikiric group studies use continuous dosing via drinking water. This route has shown activity in ligament [4], GI [11], and spinal cord [7] models. **GI-specific effects.** For gastrointestinal applications — ulcer, fistula, mucosal protection — oral administration is expected to deliver high local concentrations at the relevant tissue. The efficacy signal for GI-targeted effects via oral route is among the strongest in the literature. In the published literature, BPC-157 capsules are not studied; oral administration uses liquid gavage or drinking-water dosing. ## Subcutaneous vs Intramuscular Administration Routes in Studies The published rodent literature primarily uses intraperitoneal injection. The 2022 pharmacokinetic study compared IV and IM routes in rats and dogs [19], finding IM bioavailability of 14-19% in rats and 45-51% in dogs. The IM route is significantly less bioavailable than IV. The study did not include subcutaneous administration. For musculoskeletal studies, intraperitoneal injection is the most common route. A subset of studies — including the ligament study [4] — use peroral or topical delivery and observe similar outcomes. ## BPC-157 reconstitution in research protocols Published research protocols for BPC-157 typically dissolve lyophilized (freeze-dried) peptide in bacteriostatic water at concentrations of 1-2 mg/mL. The stability notes in the literature indicate that BPC-157 is stable in bacteriostatic water for several weeks when refrigerated — consistent with its origin protein's stability in the gastric acid environment. ## Onset of observed effects in research timelines In rodent musculoskeletal studies, measurable acceleration of tissue healing has been observed within 7-14 days of daily dosing. The ligament study measured improvements at multiple timepoints from day 7 through day 90 [4]; the muscle studies measured complete reversal of impaired healing by day 14 [6]. In neurological models, the timeline is shorter. The hippocampal ischemia-reperfusion study observed full functional recovery within 24-72 hours of a single local application in rats [8]. The spinal cord compression model showed progressive recovery from day 4 onward with full recovery by day 7 in treated animals [7]. No validated human timeline data exists. ## References [4] Cerovecki T, et al. J Orthop Res. 2010;28(9):1155-1161. PMID: 20225319. DOI: 10.1002/jor.21107 [5] Krivic A, et al. J Orthop Res. 2006;24(5):982-989. PMID: 16583442. DOI: 10.1002/jor.20096 [6] Pevec D, et al. Med Sci Monit. 2010;16(3):BR81-88. PMID: 20190676. [7] Perovic D, et al. Curr Issues Mol Biol. 2022;44(5):1976-2004. PMID: 35678659. DOI: 10.3390/cimb44050130 [8] Vukojević J, et al. Brain Behav. 2020;10(7):e01726. PMID: 32558293. DOI: 10.1002/brb3.1726 [11] Klicek R, et al. J Pharmacol Sci. 2008;108(1):7-17. PMID: 18818478. DOI: 10.1254/jphs.fp0072161 [12] Seiwerth S, et al. Front Pharmacol. 2021;12:627533. PMID: 34267654. DOI: 10.3389/fphar.2021.627533 [19] He L, et al. Front Pharmacol. 2022;13:1026182. PMID: 36588717. DOI: 10.3389/fphar.2022.1026182 [20] Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis. Altern Ther Health Med. 2024. --- A dark-botanical reading of the BPC-157 preclinical record — thirty years of tissue-repair findings, set in ink, cited to the source, and sold by no one.